Adagio Therapeutics (ADGI) Stock Price, News & Analysis

Company Overview

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $3.40 to $4.78
• 52-Week Range: N/A
• Volume: 22,357 shs
• Average Volume: 2.27 million shs
• Market Capitalization: $504.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADGI Stock Analysis - Frequently Asked Questions

How were Adagio Therapeutics' earnings last quarter?

Adagio Therapeutics, Inc. (NASDAQ:ADGI) posted its earnings results on Sunday, November, 14th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.24.

When did Adagio Therapeutics IPO?

Adagio Therapeutics (ADGI) raised $301 million in an initial public offering on Friday, August 6th 2021. The company issued 17,700,000 shares at a price of $16.00-$18.00 per share.

What other stocks do shareholders of Adagio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adagio Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), PayPal (PYPL), Tesla (TSLA), AbbVie (ABBV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/14/2021
• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ADGI
• CIK: 1832038
• Web: adagiotx.com
• Phone: 603-252-2274
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$226.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.14%
• Return on Assets: -50.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.09
• Quick Ratio: 7.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 108,831,000
• Free Float: N/A
• Market Cap: $504.98 million
• Optionable: Not Optionable
• Beta: N/A